Seasonal Influenza – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Seasonal Influenza – Drugs In Development, 2023’, provides an overview of the Seasonal Influenza pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seasonal Influenza and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Seasonal Influenza
- The report reviews pipeline therapeutics for Seasonal Influenza by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seasonal Influenza therapeutics and enlists all their major and minor projects
- The report assesses Seasonal Influenza therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seasonal Influenza
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seasonal Influenza
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seasonal Influenza pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Adimmune CorpBioNTech SE
Centivax Inc
CHA Vaccine Institute Co Ltd
Cidara Therapeutics Inc
Cilian AG
Clover Biopharmaceuticals Ltd
Cocrystal Pharma Inc
ContraFect Corp
CSL Ltd
Curevac NV
Dynavax Technologies Corp
ENA Respiratory Pty Ltd
Etna Biotech Srl
Evrys Bio
Expres2ion Biotechnologies ApS
FluGen Inc
Georgia State University
GreenLight Biosciences Holdings PBC
GSK plc
Invivyd Inc
iosBio Pharma Ltd
Jiangsu Kangrun Biological Technology Co Ltd
LiteVax BV
Longhorn Vaccines and Diagnostics LLC
Medigen Vaccine Biologics Corp
Mercia Pharma Inc
Moderna Inc
Mynvax Pvt Ltd
New Amsterdam Sciences Inc
Novavax Inc
Ocugen Inc
Respana Therapeutics Inc
SAB Biotherapeutics Inc
Sanofi
Scientific Research Institute for Biological Safety Problems
Seqirus Ltd
Sinovac Biotech Ltd
SiVEC Biotechnologies LLC
Sumitomo Pharma Co Ltd
Sunomix Therapeutics
TechnoVax Inc
Tehran University of Medical Sciences
The Institute of Vaccines and Medical Biologicals
The University of British Columbia
University of Wisconsin Madison
Vaxart Inc
Vaxess Technologies Inc
Vaxxas Pty Ltd
Viramatix Sdn Bhd
VLP Therapeutics LLC
XBiotech Inc
Zhejiang Tianyuan Bio-Pharmaceutical Co Ltd